1994•Investigational New DrugsRequires access

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

Jorge Romaguera, Maria Alma Rodriguez, Frederick Hagemeister, Peter McLaughlin, F Swan, Dennis F. Moore, Andreas H. Sarris, Anas Younes, Debbie Hill, Fernando Cabanillas

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Etoposide, Ifosfamide, Mitoxantrone, Medicine, Mesna, Salvage therapy, Refractory (planetary science), Methylprednisolone

Back to paper search Browse research topics Original source

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas — Research Paper | ScholarLens